Chemicals and biotechnology company Lonza has opened its pharmaceutical Drug Product Services laboratory in the Stücki Science Park Basel (CH), Switzerland.
The new 1,300m2 facility will initially carry out formulation development, drug product analytical development and quality control to advance customers’ drug product development programmes.
Go deeper with GlobalData
The drug development programmes will comprise formulation, stability, primary packaging, process development, and manufacturing to ensure usability and patient safety.
Lonza CEO Richard Ridinger said: “We chose Basel for Lonza’s first-ever drug product development facility because it offers us access to the latest technologies and world-leading experts in a central location, one that’s a hub of innovation in the pharma industry.”
Ridinger added: “The addition of drug product development services to Lonza’s global offerings is the next part of our journey along the healthcare continuum, a step that moves us closer to our customers and their patients.”
The Lonza lab will provide services such as particle testing or container closure integrity testing to enable production of safer medicines, as well as services to trace impurities in pharmaceutical products such as detecting extractables and leachables from plastics used in manufacturing.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataImage: Lonza has opened its pharmaceutical Drug Product Services laboratory in Switzerland. Photo: Courtesy of Lonza.
